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Hyperthyroidism related to Graves’ disease is associated with a suppression of
TSH values which may persist after surgery in spite of a LT4 replacement therapy
at non-TSH-suppressing doses. The aim of this retrospective study was to evaluate the
time to TSH normalization in a group of patients who underwent total thyroidectomy for
Graves’ disease receiving a LT4 therapy dose regimen based on a previously published
nomogram, and to identify possible correlations between the time to normalization
of post-operative TSH values and preoperative clinical and biochemical parameters.
276 patients affected by Graves’ disease who underwent surgery between 2010 and
2015, were retrospectively evaluated for clinical and biochemical parameters as well as
post-surgical LT4 treatment regimen. Of the 276 subjects, 174 had initiated LT4 dosage
corresponding to a previously published nomogram. 59 patients were excluded because
their LT4 requirement (in mcg/kg/day) changed and deviated from the nomogram during
the follow-up period, 15 patients were excluded because their TSH level was >4 mcU/ml
during the first biochemical evaluation and 2 patients were excluded because they
had low TSH levels potentially related to central hypothyroidism due to concomitant
hypopituitarism. Therefore, 98 patients were included in our statistical analysis. TSH and
FT4 were evaluated at the first post-operative assessment and during follow up until the
normalization of TSH values was achieved, and then included in the analysis. During the
first post-operative evaluation 2 months after surgery, 59/98 patients had TSH values
in the normal range (0.4 to 4.0 mcU/ml), while 39/98 patients had a TSH value < 0.4
mcU/mL. The persistence of post-operative TSH levels < 0.4 mcU/ml was significantly
correlated (p = 0.022) with longer duration of the disease. The value of anti-TSH receptor
autoantibodies (TrAb) at the diagnosis of hyperthyroidism, significantly correlated (p =
0.002) with the time to TSH normalization in the group of patients with TSH< 0.4 mcU/ml
at first control. This retrospective analysis confirms that in subjects who have undergone
thyroidectomy for Graves’ disease, time to normalization of TSH may be prolonged.
Hence, the role of TSH as the “gold standard” to assess the appropriate LT4 replacement
therapy regimen during the initial months following surgery may need to be reconsidered.
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INTRODUCTION
Total thyroidectomy is considered a reasonable ablative option
for selected patient affected by Graves’ disease when medical
therapy is unsuccessful and radioiodine ablation is not feasible
or it is contraindicated (1). Since total thyroidectomy provides
an immediate resolution of the hyperthyroidism, levothyroxine
(LT4) substitutive therapy must be started immediately after
surgery and TSH levels must be assessed at least 6–8 weeks
later in order to determine the need for dose-adjustment so to
reach and maintain post-operative TSH values within the normal
reference range.
Several strategies for the evaluation of the LT4 starting dose
after surgery for benign thyroid disease have been proposed
(2). While body weight represents a relevant factor in the
prediction of the LT4 starting dose (3), it certainly is not the
only parameter. In particular, our recently published nomogram
considers other factors such as age and body mass index (BMI)
(3), with LT4 requirement ranging from 1.8 mcg/kg (for subjects
<40 years and with BMI < 23 kg/m2) to 1.4 mcg/kg (for
subjects > 55 years and with BMI > 28 kg/m2). This proposed
nomogram allows to the achievement of “normal” TSH values
(i.e., 0.4–4 mcU/mL) in 68% of patients at the first post-surgical
evaluation (3).
Post-surgical hypothyroidism for Graves’ disease represents a
peculiar model. In fact, for a variable time between the disease
onset and surgery, the hyperthyroidism causes a suppression of
TSH values which may persist after surgery in spite of a LT4
replacement therapy aimed at obtaining normal TSH values, as
often seen in the clinical practice.
The aim of this retrospective study is to evaluate the
time of TSH normalization in patients who underwent total
thyroidectomy for Graves’ disease and who were treated with
LT4 therapy based on our previously published nomogram
(3), and to evaluate possible correlations between the
time of TSH normalization and preoperative clinical and
biochemical parameters.
MATERIALS AND METHODS
We retrospectively evaluated 276 patients affected by Graves’
disease who underwent surgery between 2010 and 2015. Total
thyroidectomy has been performed by the same surgeon in
our Institution (Catholic University School of Medicine, Rome).
All patients underwent pre- and post-surgical clinical and
biochemical evaluations in our Institution.
Retrospective analysis of the clinical parameters included:
- gender;
- age at the diagnosis and at the time of surgery;
- duration of disease;
- medium dosage of anti-thyroid drug used for the medical
treatment of hyperthyroidism and immediately before surgery;
- final histology;
- body mass index (BMI) [kg/m2]
- LT4 dosage (expressed in mcg/kg/day) prescribed after surgery
and during each biochemical control.
TABLE 1 | Nomogram for the prediction of LT4 (mcg/kg/day) starting dose after
total thyroidectomy (Adapted by Di Donna et al.(3).
BMI
≤ 23 23–28 >28
AGE
≤40 1.8 1.7 1.6
40-55 1.7 1.6 1.5
>55 1.6 1.5 1.4
BMI: kg/m2; age: years; LT4 dose: mcg/kg/day.
Retrospective analysis of the biochemical parameters
included:
- thyroid function test and anti-TSH receptor autoantibodies
(TrAb) at the onset of hyperthyroidism and immediately
before surgery;
- TSH and FT4 at the first evaluation (2 months after surgery);
- for patients who did not reach normal TSH values at the first
check, TSH and FT4 were further performed about every 4
months until the normalization of TSH.
Thyroid ultrasound to exclude significant remnant thyroid tissue
after surgery was performed using a real-time ultrasound (10–12
MHz linear transducer).
Biochemical evaluations were performed in the same
laboratory of our institution. TSH, FT4, and FT3 results were
measured by chemiluminescent assays. Analytical sensitivity of
TSH, FT3, and FT4 is < 0.0025 mcU/mL, < 1 pg/ml and <
4 pg/ml, respectively. For TrAb, electrochemiluminescent IMA
(Roche Diagnostics, Mannheim, Germany) on Cobas E 8,000
platform was used. Cut-off value suggested by the manufacturer
was 1.75 U/L.
We classified patients on the basis of age and BMI and
evaluated the dosage of LT4 (mcg/kg) prescribed after surgery.
We retrospectively included only 174 patients who after
surgery had started LT4 which corresponded to the dose
calculated according to our previously published nomogram
(Table 1). Among these 174 patients:
- 59 were excluded because their LT4 requirement (in
mcg/kg/day) changed and deviated from the nomogram
during the follow-up period, for example, for significant
weight variations or for clinical reasons which suggest to
increase or to reduce the posology. In other words, we have
considered in the statistical analysis only the patients in which
the LT4 requirement remained unchanged over time. In this
way, we can reasonably suppose that changes in TSH levels are
not related to change in LT4 requirement;
- 15 patients were excluded because their TSH level was > 4
mcU/ml during the first biochemical evaluation;
- 2 patients were excluded because they had low TSH
levels potentially related to central hypothyroidism due to
concomitant hypopituitarism. In these patients, affected by
empty sella and pituitary macroadenoma, pituitary function
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test revealed a hypopituitarism (TSH, GH and gonadotropin
deficiency and panhypopituitarism, respectively).
After these selection criteria, 98/174 patients were included in the
statistical analysis. “Normal TSH reference range” was considered
between 0.4 and 4 mcU/ml. For patients who had a TSH value
in the normal TSH reference range at the first post-operative
biochemical evaluation, we did not consider further biochemical
data during the follow-up. On the contrary, for patients who had
TSH values < 0.4 mcU/ml at the first post-operative biochemical
evaluation, we considered the following biochemical data until
“normalization” of TSH in the reference range was achieved. It is
important to underline that we considered only patients who did
not change LT4 requirement (mcg/kg/day) during their follow-up
period. On the basis of these data, we evaluated the time between
surgery and TSH normalization.
Statistical Analysis
Demographic, clinical and biochemical characteristics at
the baseline of the enrolled patients and the results of the
post-operative evaluations were described by Mean and
Standard Error for continuous variables and by frequencies and
percentages for categorical variables.
A multivariate logistic regression analysis was performed to
identify predictive factors of lack of TSH normalization at the
first biochemical evaluation. Factors included in the analysis
as explanatory variables included gender, age at diagnosis,
preoperative FT4 values, TrAb values at the diagnosis, time
between the onset of disease and surgery, dosage of anti-thyroid
drug during the medical treatment, dosage of anti-thyroid drug
before surgery, type of anti-thyroid drug and histology.
A multivariate linear regression analysis was then performed
in order to study possible associations between independent
variables (including gender, age at diagnosis, preoperative FT4
values, TrAb values at the diagnosis, time between the onset
of disease and surgery, dosage of anti-thyroid drug during the
medical treatment, dosage of anti-thyroid drug before surgery,
type of anti-thyroid drug and histology) and the duration of
TSH normalization in patients who did not reach “biochemical
euthyroidism” at their first control.
All statistical analyses were performed using STATA version
13.1 (Copyright 1985–2013 StataCorp LP, 4905 Lakeway Drive,
College Station, Texas 77845 USA) and a p< 0.05 was considered
statistically significant.
RESULTS
A total of 98 Caucasian patients (89 female and 9 male)
were included in the study. Following the diagnosis of
hyperthyroidism, patients were treated with medical therapy for
a mean of 35 months before surgery. The most commonly used
drug was methimazole (87/98, 94.6%). Final histology showed
benign disease in 91/98 patients (92.86%) and an incidentally
discovered very low-risk carcinoma in 7/98 patients (7.14%). In
all 7 cases, the tumor was a well-differentiated classical papillary
carcinoma pT1a Nx and, in consideration of the “low risk,” TSH
suppression was not considered necessary.
TABLE 2 | Clinical characteristics of the enrolled patients.
Mean standard error
Age at diagnosis (years) 36.13 1.17
Age at surgery (years) 38.84 1.19
Time between the onset of disease and surgery (months) 35.11 3.34
Dose of MTM used during the treatment (mg) 10 0.13
Dose of MTM used immediately before surgery (mg) 7.5 0.16
Dose of PTU used during the treatment (mg) 125 0.11
Dose of PTU used immediately before surgery (mg) 150 0.09
Body mass index at the time of surgery 24.39 0.37
LT4 dose after surgery (mcg/kg/day) 1.67 0.01
TrAb at the diagnosis (U/L) 13.29 1.31
FT4 before surgery (pg/ml) 13.78 0.67
FT3 before surgery (pg/ml) 4.7 0.27
MTM, methimazole; PTU, propylthiouracil; Anti-TSH receptors autoantibodies normal
values are < 1.75 U/L, as suggested by the manufacturer.
The daily mean dosage of LT4 used in the post-operative phase
was 1.67 mcg/kg.
Baseline clinical and biochemical characteristics of enrolled
patients are presented in Table 2 and the results of the statistical
analyses are described in Table 3.
During the first post-operative evaluation, 59/98 patients
(60.2%) had TSH values in the normal range (between 0.4 and
4.0 mcU/ml), while the remaining 39/98 patients (39.8%) had a
TSH value < 0.4 mcU/ml (Table 2). For patients who had a TSH
values < 0.4 mcU/ml, we considered the following biochemical
data (TSH and FT4 every 4months) until “normalization” of TSH
in the reference range was achieved. During the TSH-suppressive
phase, patients were not clinically thyrotoxic. It is important to
underline that LT4 replacement dose in this group of patients
is the same established by the nomogram and the final stable
dose of LT4 (mcg/kg/day) after TSH normalization is the same
used during TSH suppression period. Therefore, the biochemical
TSH “normalization” can be considered not dependent by LT4
replacement dose changes.
The multivariate logistic regression analysis, aimed at
identifying predictive factors of lack of TSH normalization at
the first biochemical evaluation, showed that a longer duration
of the disease before surgery significantly correlated (p = 0.022)
with the persistence of TSH levels < 0.4 mcU/ml (Table 3). In
patients with normal TSH levels at the first biochemical control
the mean time between the onset of disease and surgery was
30.08 months (SE 3.26). For patients with TSH < 0.4 mcU/mL
at the first biochemical control, the mean time between the onset
of disease and surgery was 42.87 months. Therefore, patients
who reached “biochemical euthyroidism” at the time of the first
laboratory evaluation (2 months after surgery) had a shorter
duration between disease onset and surgery (figure 1).
Results by multivariate linear regression also showed that the
value of TrAb at the diagnosis of Graves’ disease, significantly
correlated (p= 0.002) with the time to TSH normalization in the
group of patients who had TSH < 0.4 mcU/ml at the first control
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TABLE 3 | Factors predicting the lack of TSH normalization at the first
biochemical valuation.
p-value
Gender 0.229
Age at diagnosis 0.589
Preoperative FT4 values 0.248
TrAb values at the diagnosis 0.223
Time between the onset of disease and surgery 0.022
Dosage of anti-thyroid drug during the medical treatment 0.783
Dosage of anti-thyroid drug before surgery 0.356
Type of anti-thyroid drug 0.283
Histology 0.172
Bold values indicate a significant correlation.
FIGURE 1 | The longer duration of the disease before surgery correlates with
the persistence of TSH levels < 0.4 mcU/ml. Patients who reached
“biochemical euthyroidism” 2 months after surgery, had a shorter duration of
disease between the onset of hyperthyroidism and surgery.
(Table 4, figure 2). The mean value of TrAb at the diagnosis in
this group was 14.27 U/L.
DISCUSSION
This retrospective analysis represents the first study in the
literature evaluating the time to normalization of TSH values
in patients who underwent total thyroidectomy for Graves’
disease. Furthermore, the relationship between time to TSH
normalization and clinical and biochemical variables has been
evaluated. Indeed, while common clinical practice suggests that,
using a standard post-surgery LT4 dosage, TSH normalizes
more slowly in thyroidectomized patients for Graves’ disease,
to our knowledge no studies have been performed to better
characterize this phenomenon and to identify possible predictive
factors. Our study confirmed the delay in post-surgical TSH
TABLE 4 | Variables associated with the duration of TSH normalization in patients
who did not reach “biochemical euthyroidism” at first post-operative biochemical
control.
p-value
Gender 0.629
Age at diagnosis 0.076
Preoperative FT4 values 0.678
TrAb values at the diagnosis 0.002
Time between the onset of
disease and surgery
0.957
Dosage of anti-thyroid drug
during the medical treatment
0.567
Dosage of anti-thyroid drug
before surgery
0.691
Type of anti-thyroid drug 0.627
Histology 0.615
Bold values indicate a significant correlation.
normalization following thyroidectomy due to Graves’ disease
and an association between this phenomenon and patients’
clinical (duration of hyperthyroidism before surgery) and
biochemical (TrAb values) pre-surgical parameters was found.
About the possible correlation between pre and post-operative
TSH levels, in our opinion, the presence of hyperthyroidism and
the influence of the antithyroid drugs make pre-operative TSH
not reliable. To obtain a model in which TSH normalization
is independent of LT4 dosage variations, we considered in
our statistical analysis only patients who did not modify their
LT4 requirement (mcg/kg/day) during biochemical follow-up. A
reasonable TSH reference range which can be applied to monitor
LT4 substitutive therapy is between 0.4 and 4 mcU/mL. Indeed,
several studies that evaluated “normal” TSH values in the general
population reported that the lower TSH limit (2.5th percentile)
lies between 0.2 and 0.4 mcU/mL, while upper limits (97.5th
percentile) vary between 2.4 and 4.2 mcU/mL, and appear to be
related to ethnicity or geographic location (4).
In the present study only about 60% of patients with
Graves’ disease achieved normal TSH values at the first post-
operative biochemical evaluation. Therefore, the performance
of the previously published nomogram for the estimation
of LT4 replacement therapy (3), which was retrospectively
evaluated in this group, resulted to be lower than that
observed in patients thyroidectomized for other benign diseases.
Furthermore, considering that patients with TSH > 4 mcU/mL
have been previously excluded from the statistical analysis,
all the patients who did not reach normalization of TSH
during first post-operative biochemical evaluation, had TSH
values < 0.4 mcU/mL.
The longer duration of disease before surgery represents a risk
factor for not reaching normalization of TSH at the time of the
first biochemical evaluation.
A similar behavior can be observed in patients who, after
having undergone surgery for differentiated thyroid cancer and
are then being treated with LT4 suppressive dose, switch to a
substitutive dose regimen. This phenomenon has been described
in a recent study which showed long-term pituitary suppression
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FIGURE 2 | Multivariate linear regression analysis showed a correlation
between higher value of TrAb at the diagnosis and longer time of TSH
normalization in the group of patients who had TSH < 0.4 mcU/ml at the first
biochemical evaluation.
in patients who had been treated with TSH suppressive dose
of LT4 for a long period following surgery for differentiated
thyroid carcinoma (5). In this cohort, even 6 months appear to
be not enough for TSH secretion to be restored and to allow the
evaluation of thyroid hormone status by measuring serum TSH.
The authors suggested that this phenomenon may be due to a
long-term suppressive effect exerted by the “excess” of LT4, which
delays the recovery of the feedback mechanism (5). Similarly, in
our group of patients, the persistence of suppressed TSH values
can be explained by considering the prolonged TSH suppression
induced by the hyperthyroidism.
It is well known, as shown by previous studies, that in the
medical treatment of Graves’ disease, serum TSH levels may
remain low or suppressed for several months to years, despite
normalization of FT3 and FT4 (6). Several mechanisms have
been proposed to explain the persistence of TSH suppression
after therapy. A systematic review, evaluating 18 articles
on this topic, proposed different possible mechanisms (7).
Some studies, demonstrated the evidence of a “thyrotroph
atrophy,” hypothesizing that this can contribute to the
prolonged suppression (8). The histological evaluation of
the pituitary performed post-mortem in patients who died
during thyrotoxicosis, shows a pronounced decrease or loss of
immunoreactivity to TSH, without morphological differences
between Graves’ disease or Plummer’s disease or between
genders. However, the loss of pituitary TSH immunoreactivity
was found to be reversible in patients with hyperthyroidism
after medical treatment, as demonstrated in 16 additionally
concurrently studied patients who were in thyrotoxicosis
but have been successfully treated with medical therapy and
subsequently had normal thyroid function or ypothyroidism (9).
Other studies involved the autocrine and paracrine feedback
exerted by TSH at pituitary and hypothalamic levels (10)
[ultra-short and short feedback, respectively (11)]. In fact, TSH
receptors have been identified on folliculo-stellate cells of the
pituitary as well as astroglial cells of the hypothalamus. These
receptors are recognized by their specific autoantibodies and
are able to downregulate TSH secretion directly or by reducing
TRH, independently from thyroid hormone levels (11). The
role of immuno-mediated processes, involving the TrAb, has
been emphasized by other Authors (12–14). This mechanism
probably involves also deiodinase activity, as demonstrated in
hyperthyroid sera with TrAb in which the activity of type 2
deiodinase is increased (15).
The time of recovery of TSH has been evaluated in several
studies (12, 13, 16–18). Clinical data suggest that TSH recovery
is most likely to occur within the first 6 months after treatment,
with recovery being achieved in approximately 70% of patients
(7). The larger cohort study retrospectively evaluated patients
for as long as 30 months, showing that 85.7% of patients have
recovered TSH at 30months (13). In our study, TSH recovery has
been reached in 78.9% of patients until 20 months after surgery.
The mean time of TSH normalization was about 17 months and
normalization was obtained maintaining the same LT4 dosage
calculated in mcg/kg/day.
Interestingly, the majority of the studies have been conducted
in preclinical models, and clinical studies have been limited
to patients who reached the remission from Graves’ disease
by medical therapy or after radioiodine ablation. Instead, data
from patients who underwent total thyroidectomy for Graves’
disease are lacking. In our opinion, total thyroidectomy is
the most accurate model to confirm the delayed recovery of
TSH after remission from Graves’ disease since it completely
and instantaneously removes the confounding effect of any
residual thyroid function on post-surgical hormonal assessment.
Furthermore, this model allows comparing the trend of TSH
values matching them with those of patients who underwent
surgery for other disease. To demonstrate this different trend in
Graves’ disease, we selected only patients who were treated with
a LT4 dosage targeted to obtain a TSH level in the substitutive
dosage reference range.
An interesting finding deduced by our evaluation is the
possible role of TrAb in predicting the time of TSH recovery.
In fact, the levels of TrAb at the diagnosis of Graves’ disease
significantly affects the time of TSH normalization during the
post-surgical follow-up. Higher TrAb levels at the diagnosis of
hyperthyroidism are significantly associated with a longer time
of TSH recovery. In our study, all patients with persistence
of TSH suppression during the first post-operative evaluations,
mean TrAb values at the diagnosis were about 8-fold higher
than the normal reference range (14.5 U/L, n.v. < 1.75). There
is evidence reported in literature that TrAb play a role in
regulating TSH secretion. In fact, Graves’ disease is the only
cause of hyperthyroidism based on an autoimmune etiology and,
with the discovery of TSH receptors within the brain, it has
been proposed that TrAb may be involved in the regulation
of negative feedback (12). The first observations have been
reported in Guinea pigs, in which lower TSH levels have been
detected after the injection of IgG from patients with Graves’
ophthalmopathy (19). In a clinical study evaluating the thyroid
status during treatment with thionamides, higher TrAb values are
significantly correlated with suppressed TSH (20), as confirmed
also by other Authors(14). An inverse relationship between TrAb
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and TSH levels may be observed both in euthyroid rats and in
euthyroid humans, remarking an active role by autoantibodies in
suppressing TSH (13, 14).
A significant limitation of our study, related to the
retrospective evaluation, is the lack of TrAb values at the time
of TSH normalization. However, the positive correlation between
TrAb values at the diagnosis of hyperthyroidism and persistently
suppressed TSH levels after surgery, suggest the possibility of
a more complex mechanism, involving a persistent activity of
TrAb on negative feedback, until several months after surgery.
This phenomenon should be analyzed by prospective studies on
this topic.
CONCLUSIONS
This retrospective analysis confirms that TSH normalizes
slowly in patients who achieve remission for Graves’ disease.
To our knowledge, this represents the first study on this
topic, focused on post-surgery hypothyroidism, while other
previous studies were focused on the trend of TSH levels
after medical therapy or radioiodine ablation. In our analysis,
the persistence of reduced TSH levels is associated with
a longer duration of disease before surgery, and the time
to TSH normalization correlates with higher TrAb levels
at the diagnosis of hyperthyroidism. Aside from possible
physio-pathological hypotheses on the regulation of the
hypothalamus-pituitary-thyroid axis, the results of our study
offer useful suggestions for clinical practice. In fact, in patients
affected by Graves’ disease, the TSH value alone cannot be
considered as the “gold standard” in evaluating the efficacy
of the LT4 replacement therapy during the first months after
surgery. It is, therefore, reasonably to avoid the reduction of
LT4 therapy in presence of reduced TSH levels when patients
present clinically with “euthyrodism.” Furthermore, TSH
should be monitored periodically considering that the mean
time to TSH normalization in the majority of these patients is
about 17 months.
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